Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Current Status of Glucocorticoid Usage in Solid Organ Transplantation

Version 1 : Received: 15 June 2021 / Approved: 16 June 2021 / Online: 16 June 2021 (10:30:41 CEST)

How to cite: Dashti-Khavidaki, S.; Saidi, R.; Lu, H. Current Status of Glucocorticoid Usage in Solid Organ Transplantation. Preprints 2021, 2021060437 (doi: 10.20944/preprints202106.0437.v1). Dashti-Khavidaki, S.; Saidi, R.; Lu, H. Current Status of Glucocorticoid Usage in Solid Organ Transplantation. Preprints 2021, 2021060437 (doi: 10.20944/preprints202106.0437.v1).

Abstract

Glucocorticoids (GCs) have been the mainstay of immunosuppressive therapy in solid organ transplantation (SOT) for decades due to their potent effects on the innate immunity and tissue protective effects. But, some SOT centers are reluctant to administer GCs for long-time due to the various side effects. This review summarizes advantages and disadvantages of GCs in SOT. PubMed and Scopus databases were searched from 2011 to April 2021 using search syntaxes cover “transplantation” and “glucocorticoids”.GCs are used in transplant recipients, transplant donors, and organ perfusate solution to improve transplant outcomes. In SOT recipients GCs are administered as induction and maintenance immunosuppressive therapy. GCs are also the cornerstone to treat acute anti-body- and T-cell-mediated rejections. Addition of GCs to organ perfusate solution and pretreatment of transplant donors with GCs are recommended by some guidelines and protocols to reduce ischemia-reperfusion injury peri-transplant. GCs with low bioavailability and high potency for GC receptors such as budesonide, nanoparticle-mediated targeted delivery of GCs to specific organs, and combination use of dexamethasone with inducers of immune-regulatory cells are new methods of GC usage in SOT patients to reduce side effects or induce immune-tolerance instead of immunosuppression. Various side effects on different non-targeted organs/tissues such as bone, cardiovascular, neuromuscular, skin, and gastrointestinal tract have been noted for GCs. There are also potential drug-drug interactions for GCs in SOT patients.

Keywords

Corticosteroids; Glucocorticoids; Solid organ transplantation; Liver; Kidney; Heart; Lung

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.